in ,

Migraine Prevention in 2026: New Evidence and Access Gaps

Medically Reviewed & Fact-Checked
By Dr. Ahmed Farhan, MBBS, FCPS (Assistant Professor of Medicine)
Updated:

Medical Disclaimer: This article is for educational and informational purposes only and does not constitute individual medical advice, diagnosis, or clinical treatment. Always consult your personal physician or qualified healthcare provider regarding medical conditions, prescription changes, or new health regimens.

Transparency Disclosure: Dibesity features independent, evidence-based medical research. Some articles may contain vetted affiliate links to metabolic wellness products; if you make a purchase, we may earn a modest commission at no extra cost to you.

| Sources: PubMed-indexed research

Introduction

Migraine is a common neurological condition that can cause intense headache attacks, nausea, and sensitivity to light and sound.

For people who have frequent attacks, preventive treatment aims to make attacks less frequent and less disabling. Several newer preventive medicines have entered clinical use in recent years, and researchers are now asking practical questions: Which treatment works best for which person, when should it start, and how long should it continue?

This article reviews five recent publications on migraine prevention. It is based only on their abstracts and published summaries, not on full study texts. It also explains where the evidence is strong, where it is still developing, and where important gaps remain.

What Is Migraine Prevention?

Migraine treatment usually comes in two forms. Acute treatments are taken during an attack to relieve pain. Preventive treatments are taken regularly, often every day, to reduce how many attacks a person has over time.

Preventive medicines fall into two broad groups. Conventional preventives are older drugs that were developed for other purposes but are also used for migraine, such as topiramate.

CGRP-targeted therapies are newer medicines designed specifically for migraine. CGRP stands for calcitonin gene-related peptide, a signaling molecule involved in pain pathways.

These medicines include monoclonal antibodies, which are large protein drugs given by injection, and small-molecule CGRP receptor antagonists, which are pills that block the receptor CGRP acts on. Atogepant is one of these oral pills.

Why Does It Matter?

Migraine can interfere with work, school, family life, and sleep. Choosing a preventive treatment is often a balance between benefit and side effects.

A medicine that reduces attacks but causes side effects that people cannot tolerate may not be useful in everyday life.

This is why the latest research looks at both effectiveness and tolerability. It also explains why timing and duration matter. A treatment that is started early, or continued long enough to work, may help more people than one that is stopped too soon.

What Does the Latest Research Show?

A head-to-head comparison: atogepant versus topiramate

Most migraine preventive studies compare a drug with a placebo, which is an inactive pill. Direct comparisons between two active drugs are much rarer.

The TEMPLE trial was designed to fill this gap by comparing atogepant 60 mg once daily with topiramate, a conventional preventive, in adults with migraine across 12 countries [1].

In the 24-week double-blind period, 12% of people taking atogepant stopped treatment because of side effects, compared with 30% of those taking topiramate [1]. Treatment-related side effects were also reported less often with atogepant (56%) than with topiramate (78%) [1].

The trial also found that more people on atogepant had at least a 50% reduction in monthly migraine days (64%) than those on topiramate (39%) [1].

Expert interpretation: These results suggest that atogepant may be easier to tolerate than topiramate for many people.

Because topiramate is often limited by side effects, this matters in real life. However, the trial was funded by the drug’s manufacturer, and the full long-term picture is not yet available. The open-label extension period was still ongoing when the results were reported [1].

A broader look at preventive options

A systematic review by the American Academy of Neurology and the American Headache Society examined 217 randomized controlled trials of migraine preventive drugs in adults [2].

For episodic migraine, which means fewer than 15 headache days per month, the review found high-confidence evidence that galcanezumab and erenumab reduce headache frequency more than placebo [2].

It found moderate-confidence evidence for atogepant, eptinezumab, fremanezumab, topiramate, valproate, and propranolol [2].

For chronic migraine, high-confidence evidence supported fremanezumab, galcanezumab, and onabotulinumtoxinA [2].

Moderate-confidence evidence supported atogepant, eptinezumab, erenumab, topiramate, and valproate [2]. Several treatments also improved patient-reported quality of life on validated questionnaires [2].

The review also stated that comparisons between active treatments were limited and generally low confidence [2]. This is why head-to-head studies like TEMPLE are important.

Pooled data on atogepant

A systematic review and meta-analysis of six randomized trials, including 3,453 patients, looked specifically at atogepant [5].

Compared with placebo, atogepant reduced monthly migraine days, monthly headache days, and use of acute migraine medicines across the tested doses [5].

The authors reported that atogepant remained effective in people with chronic migraine and in those with headaches linked to medication overuse [5].

The same analysis found that the overall risk of side effects was slightly higher with atogepant than with placebo [5].

Common side effects included nausea, constipation, fatigue, and decreased appetite, and most were mild to moderate [5]. The authors noted that the 30 mg twice-daily regimen may have been linked to more side effects [5].

Guidelines and practical recommendations

A companion practice guideline from the same American groups gives recommendations on when to start a preventive medicine and how to choose one [3].

It addresses special situations, including patients with fibromyalgia, obesity, or high blood pressure, older adults, pregnancy and breastfeeding, sex-related factors, and people who overuse acute medicines [3].

Because the approved abstract does not list the specific recommendations, readers should consult the full guideline and their own doctors for details.

The 2026 Taiwan Headache Society guideline focuses on CGRP-targeted therapies [4]. It recommends preventive treatment for people who have at least 4 headache days per month, significant disability, or failure of or intolerance to acute treatment, among other situations [4].

The guideline lists CGRP-targeted therapies as a first-line option for both episodic and chronic migraine [4]. It also states that a person does not need to fail several other preventives before starting one [4].

How Do These Treatments Work?

Migraine involves changes in nerve signaling in the brain and the nerves around it. CGRP is one of the molecules involved in this process. Blocking CGRP or its receptor is thought to reduce pain signaling, which is why these drugs were developed.

Researchers have studied the biology of migraine in laboratory and animal models for decades. Those findings help explain why CGRP is a target. However, a plausible mechanism does not prove that a drug works in people. Clinical trials are what show whether a treatment reduces attacks safely.

Who May Benefit?

The guidelines suggest that preventive treatment may be considered for people with frequent attacks, significant disability, or problems with acute medicines [3][4].

Whether a person should start a preventive, and which one, depends on their health history, other conditions, preferences, and risks.

  • People with frequent or disabling attacks may be candidates for prevention, as described in the Taiwan guideline [4].
  • People who have not tolerated older preventives may consider alternatives, based on the TEMPLE tolerability findings [1].
  • People with chronic migraine or medication overuse headache may have options supported by moderate or high-confidence evidence [2][5].

Clinicians and patients should weigh these possibilities together. This article does not determine who should receive any specific treatment.

Practical Implications

Timing

The Taiwan guideline suggests that early treatment may give better control than delayed treatment [4]. This is a guideline-based opinion, not a result proven in a single trial comparing timing directly.

Duration

The same guideline states that CGRP-targeted therapy may be continued for up to 12 months in both episodic and chronic migraine [4].

It emphasizes continuing treatment rather than stopping it prematurely [4]. Decisions about stopping should always be made with a doctor, because the right timing depends on each person’s response and side effects.

Access

Many people cannot get the medicine they need. Drug availability and insurance coverage differ between countries, so guidelines and recommendations may not translate directly into care everywhere.

The research reviewed here does not measure real-world access, and it does not include large real-world cohort studies that track outcomes in routine practice.

Risks and Safety Concerns

Side effects are an important part of every migraine preventive decision. In TEMPLE, one serious adverse event, an anaphylactic reaction, was judged related to atogepant.

Six people had serious adverse events on atogepant and three on topiramate. No deaths were reported [1]. These numbers are small, so they cannot rule out rare risks.

The meta-analysis found that atogepant was generally well tolerated, but it also found a slightly higher risk of side effects than placebo [5].

Topiramate is associated with side effects that often lead people to stop it [1]. Other CGRP-targeted medicines may have different side effect profiles, and the research reviewed here does not compare them in detail.

Pregnancy, breastfeeding, older age, high blood pressure, and other health conditions can change which medicine is appropriate. Anyone considering a preventive should discuss these factors with a qualified clinician.

Limitations of Current Research

  • This article is based on abstracts and summaries only, not full study texts.
  • Few trials compare active medicines directly, so many comparisons are indirect and of lower confidence [2].
  • The TEMPLE trial was funded by the manufacturer of atogepant, and its open-label period was still ongoing [1].
  • Most TEMPLE participants were women (89%) and most were White (96%), which may limit how well the results apply to other groups [1].
  • The atogepant meta-analysis pooled short-term trials, so long-term safety remains unclear [5].
  • Evidence for some forms of migraine, such as vestibular migraine, is limited, and the approved sources do not address them directly.
  • Guidelines differ between countries, partly because of drug access and reimbursement rules [3][4].

Frequently Asked Questions

Is atogepant better than topiramate?

In the TEMPLE trial, atogepant led to fewer stops due to side effects and a larger reduction in monthly migraine days over 24 weeks [1]. This is a single trial over a limited period, so it does not prove that atogepant is better for every person.

Are CGRP treatments the first choice for everyone?

The Taiwan guideline lists CGRP-targeted therapies as first-line options [4]. Other guidance, including the American guidelines, covers a range of drugs, and the best choice depends on the individual [2][3].

How long should preventive treatment continue?

The Taiwan guideline suggests CGRP-targeted therapy may be continued for up to 12 months [4]. Any decision to stop or continue should be made with a doctor.

Does preventive treatment work for chronic migraine?

Several treatments, including atogepant, erenumab, fremanezumab, galcanezumab, and onabotulinumtoxinA, have evidence in chronic migraine at high or moderate confidence [2][5].

Are these medicines safe?

Most side effects in the reviewed studies were mild to moderate, but side effects do occur and some are serious [1][5]. Long-term safety data are still developing.

Key Takeaways

  • New research suggests atogepant may be better tolerated than topiramate, based on one head-to-head trial [1].
  • Several migraine preventives have good evidence of benefit, though direct comparisons remain limited [2].
  • Guidelines now recommend CGRP-targeted therapies as first-line options in some regions [4].
  • Early treatment and continuing therapy for an appropriate period may be considered, but decisions must be individualized [3][4].
  • Access, long-term safety, and evidence for some migraine types remain important gaps.

Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Consult a qualified healthcare professional before making treatment decisions.

References

  1. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial. DOI: https://doi.org/10.1016/s1474-4422(26)00214-0
  2. Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society. DOI: https://doi.org/10.1212/wnl.0000000000218112
  3. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. DOI: https://doi.org/10.1212/wnl.0000000000214881
  4. The 2026 Taiwan headache society guideline on the use of treatments targeting the CGRP pathway. DOI: https://doi.org/10.1097/jcma.0000000000001446
  5. Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. DOI: https://doi.org/10.7759/cureus.112994

Recommended Metabolic Health & Wellness Products

A curated index of metabolic support compounds, prebiotic fibres, functional botanicals, and zero-sugar pantry staples selected for ingredient quality and scientific relevance.

Editorial Integrity & Medical Disclaimer: All content on Dibesity.com is created for educational and informational purposes. Product listings do not constitute medical advice, disease management protocols, or an endorsement of specific health outcomes. Always consult your qualified healthcare provider before introducing new nutritional supplements.

Transparency Notice: As an Amazon Associate, Dibesity.com earns from qualifying purchases made through external affiliate links, at no extra cost to you.

Targeted Metabolic & Cellular Support

Apigenin Powder

A bioflavonoid compound explored for cellular protection, circadian rhythm support, and metabolic balance.

View on Amazon →

97% Pure Berberine Powder (100 g)

High-purity berberine HCl powder for customizable serving sizes and metabolic pathway support.

View on Amazon →

Berberine Powder (200 g)

Bulk berberine powder formulation. Check the listing for ingredient details, certificates of analysis, and reviews.

View on Amazon →

Pure Inositol Powder

Pure Myo-Inositol and D-Chiro-Inositol powder formulation for metabolic and reproductive wellness. Check the listing for details.

View on Amazon →

Functional Botanicals & Prebiotic Fibres

Psyllium Husk with Fennel & Cardamom

A soluble prebiotic fibre blend with warming digestive spices to support gut motility and postprandial glucose moderation.

View on Amazon →

100% Pure Hibiscus Powder

Anthocyanin-rich botanical powder supporting cardiometabolic markers, nitric oxide pathways, and vascular health.

View on Amazon →

Roasted Barley Powder

A roasted whole-grain grain alternative suitable for nutritious, caffeine-free herbal teas and warm beverages.

View on Amazon →

Allulose Confectionery (Low-Glycaemic)

Strawberry Allulose Gummies

Low-calorie, rare-sugar allulose gummies designed to satisfy sweet cravings without causing glycemic spikes.

View on Amazon →

Watermelon Allulose Gummies

Refreshing watermelon flavour sweetened with keto-compatible allulose. Minimal net impact on blood sugar.

View on Amazon →

Mixed Berry Allulose Gummies

Berry-flavoured chewable treats sweetened with rare sugar allulose for a clean, tooth-friendly profile.

View on Amazon →

Compliance Note: As an Amazon Associate, Dibesity.com earns from qualifying purchases. Prices, packaging, and availability are set directly by Amazon and participating retailers and are subject to change. Please verify current specifications and allergen warnings on the merchant listing before purchasing.

What do you think?

Written by Dr. Ahmed Farhan


Dr. Ahmed Farhan

MBBS, FCPS (Internal Medicine) | Assistant Professor of Medicine

| Consultant Physician | Specialist in Diabetes, Weight Management & Lifestyle Medicine

Founder of Dibesity | Advocate of Evidence-Based Natural Health

Antimicrobial Resistance Clinical Perspective Medium

Antimicrobial Resistance 2026: New Antibiotics, FDA Approvals & Clinical Advances